DE60000133C5 - Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen - Google Patents
Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen Download PDFInfo
- Publication number
- DE60000133C5 DE60000133C5 DE60000133.4T DE60000133T DE60000133C5 DE 60000133 C5 DE60000133 C5 DE 60000133C5 DE 60000133 T DE60000133 T DE 60000133T DE 60000133 C5 DE60000133 C5 DE 60000133C5
- Authority
- DE
- Germany
- Prior art keywords
- epa
- dha
- fatty acids
- essential fatty
- suffered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000004626 essential fatty acids Nutrition 0.000 title claims abstract 4
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims abstract 9
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims abstract 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 5
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 5
- 229940079593 drug Drugs 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 claims 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 6
- 206010042434 Sudden death Diseases 0.000 claims 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 2
- 229940000640 docosahexaenoate Drugs 0.000 abstract 2
- 229940066279 eicosapentaenoate Drugs 0.000 abstract 2
- ITNKVODZACVXDS-YATCGRJWSA-N ethyl (4e,7e,10e,13e,16e,19e)-docosa-4,7,10,13,16,19-hexaenoate Chemical compound CCOC(=O)CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CC ITNKVODZACVXDS-YATCGRJWSA-N 0.000 abstract 1
- 229960002600 icosapent ethyl Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Verwendung essentieller Fettsäuren, enthaltend eine Mischung aus Eicosapentaensäureethylester (EPA) und Docosahexaensäureethylester (DHA), zur Herstellung eines Medikaments zur Verhinderung der Sterblichkeit bei einem Patienten, der einen Herzinfarkt erlitten hat, worin der Gehalt an EPA + DHA in solch einer Mischung von 85 Gew.-% ist; und das Medikament zur oralen Verabreichung bei einer Dosierung von 0,7 bis 1,5 g täglich dient.
Description
- Der 3. Senat (Nichtigkeitssenat) des Bundespatentgerichts hat auf Grund der mündlichen Verhandlung vom 22. November 2011 für Recht erkannt:
Daseuropäische Patent 1 152 755 wird mit Wirkung für das Hoheitsgebiet der Bundesrepublik Deutschland dadurch teilweise für nichtig erklärt, dass seine Patentansprüche folgende Fassung erhalten:
Claims (5)
- Verwendung essentieller Fettsäuren, enthaltend eine Mischung aus Eicosapentaensäureethylester (EPA) und Docosahexaensäureethylester (DHA), zur Herstellung eines Medikaments zur Verhinderung der Sterblichkeit bei einem Patienten, der einen Herzinfarkt erlitten hat, worin der Gehalt an EPA + DHA in solch einer Mischung von 85 Gew.-% ist; und das Medikament zur oralen Verabreichung bei einer Dosierung von 0,7 bis 1,5 g täglich dient.
- Verwendung von Anspruch 1, worin das Medikament nützlich ist zur Verhinderung der Sterblichkeit aufgrund plötzlichen Todes bei einem Patienten, der einen Herzinfarkt erlitten hat.
- Verwendung gemäß Anspruch 1, worin das EPA/DHA-Verhältnis in der EPA + DHA-Mischung 0,9/1,5 ist.
- Verwendung essentieller Fettsäuren, enthaltend Eicosapentaensäureethylester (EPA) oder Docosahexaensäureethylester (DHA), zur Herstellung eines Medikaments zur Verhinderung der Sterblichkeit bei einem Patienten, der einen Herzinfarkt erlitten hat, worin der EPA- oder DHA-Gehalt 85 Gew.-% ist; und das Medikament zur oralen Verabreichung bei einer Dosierung von 0,7 bis 1,5 g täglich dient.
- Verwendung gemäß Anspruch 5, worin das Medikament nützlich ist zur Verhinderung der Sterblichkeit aufgrund plötzlichen Todes bei einem Patienten, der einen Herzinfarkt erlitten hat.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI000313A IT1308613B1 (it) | 1999-02-17 | 1999-02-17 | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
ITMI990313 | 1999-02-17 | ||
PCT/EP2000/000957 WO2000048592A1 (en) | 1999-02-17 | 2000-02-07 | Essential fatty acids in the prevention of cardiovascular events |
Publications (3)
Publication Number | Publication Date |
---|---|
DE60000133D1 DE60000133D1 (de) | 2002-05-23 |
DE60000133T2 DE60000133T2 (de) | 2002-11-21 |
DE60000133C5 true DE60000133C5 (de) | 2014-02-27 |
Family
ID=11381919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60000133.4T Expired - Lifetime DE60000133C5 (de) | 1999-02-17 | 2000-02-07 | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen |
Country Status (26)
Country | Link |
---|---|
US (2) | US7462643B1 (de) |
EP (2) | EP1247523A1 (de) |
JP (2) | JP5441287B2 (de) |
KR (2) | KR20070098954A (de) |
CN (1) | CN1230159C (de) |
AT (1) | ATE216230T1 (de) |
AU (1) | AU775078B2 (de) |
BR (1) | BR0008153A (de) |
CA (1) | CA2362271C (de) |
CZ (1) | CZ301307B6 (de) |
DE (1) | DE60000133C5 (de) |
DK (1) | DK1152755T3 (de) |
EA (1) | EA004312B1 (de) |
ES (1) | ES2174814T3 (de) |
HK (1) | HK1044720B (de) |
HU (1) | HUP0200111A3 (de) |
ID (1) | ID30205A (de) |
IL (2) | IL144377A0 (de) |
IT (1) | IT1308613B1 (de) |
NO (1) | NO328797B1 (de) |
NZ (1) | NZ513093A (de) |
PL (1) | PL209078B1 (de) |
PT (1) | PT1152755E (de) |
SK (1) | SK286523B6 (de) |
WO (1) | WO2000048592A1 (de) |
ZA (1) | ZA200106029B (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
ITMI20020269A1 (it) * | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
GB0210212D0 (en) * | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
CA2485116C (en) | 2002-05-03 | 2013-02-05 | Pronova Biocare As | Use of epa and dha in secondary prevention |
ITMI20022511A1 (it) * | 2002-11-26 | 2004-05-27 | Victorix Assets Ltd | Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale. |
ATE499146T1 (de) | 2005-03-11 | 2011-03-15 | Recon Oil Ind Private Ltd | Synergistisch hitzestabiles ölmedium mit eicosapentaensäure (epa) und docosahexaensäure (dha) |
CA2570763C (en) * | 2005-07-08 | 2011-08-23 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing onset of cardiovascular events |
JP5134916B2 (ja) * | 2005-07-08 | 2013-01-30 | 持田製薬株式会社 | 心血管イベント発症予防用組成物 |
WO2007071733A2 (en) * | 2005-12-21 | 2007-06-28 | Brudy Technology, S.L. | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
CN101365438A (zh) | 2006-02-07 | 2009-02-11 | 持田制药株式会社 | 预防中风复发的组合物 |
ES2500063T3 (es) | 2006-05-31 | 2014-09-29 | Mochida Pharmaceutical Co., Ltd. | Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple |
US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
MX2011001419A (es) | 2008-08-07 | 2011-05-25 | Prodotti Antibiotici Spa | Tratamiento a largo plazo de deficiencia cardiaca sintomatica. |
JPWO2010018856A1 (ja) * | 2008-08-13 | 2012-01-26 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防/改善または治療剤 |
EP2475309A4 (de) * | 2009-09-08 | 2015-07-29 | Atrium Medical Corp | Herniapflaster |
RU2014146265A (ru) | 2009-12-30 | 2015-07-10 | Басф Фарма (Калланиш) Лимитед | Способ хроматографического разделения с псевдодвижущимся слоем |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
GB201111595D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Improved process |
GB201111601D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New process |
GB201111594D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New improved process |
GB201111589D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New modified process |
GB201111591D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Further new process |
KR101681907B1 (ko) * | 2012-02-27 | 2016-12-12 | 주식회사 케어사이드 | 혈액 순환 촉진 및 피부 질환 개선용 조성물 |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
MY189576A (en) | 2012-03-30 | 2022-02-17 | Micelle Biopharma Inc | Omega-3 fatty acid ester compositions |
EP2897595B1 (de) * | 2012-09-24 | 2020-06-03 | Aker Biomarine Antarctic As | Omega-3-zusammensetzungen |
GB201300354D0 (en) | 2013-01-09 | 2013-02-20 | Basf Pharma Callanish Ltd | Multi-step separation process |
US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
US8802880B1 (en) | 2013-05-07 | 2014-08-12 | Group Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
EP3118186B1 (de) | 2013-12-11 | 2022-02-09 | Novasep Process | Chromatografische anlage zur herstellung von mehrfach ungesättigten fettsäuren |
BR112016015718B1 (pt) | 2014-01-07 | 2021-12-07 | Novasep Process Solutions | Processo de purificação de aminoácidos aromáticos |
PL237374B1 (pl) * | 2017-11-10 | 2021-04-06 | Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia | Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6034156A (ja) * | 1983-08-08 | 1985-02-21 | Hayashibara Biochem Lab Inc | エイコサペンタエン酸包接化合物及びこれを含有した飲食物 |
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
NO157302C (no) | 1985-12-19 | 1988-02-24 | Norsk Hydro As | Fremgangsmaate for fremstilling av et fiskeoljekonsentrat. |
US4920098A (en) | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
IT1205043B (it) | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
GB2218984B (en) | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US5059622A (en) * | 1989-08-29 | 1991-10-22 | Biosyn, Inc. | Method for reducing blood pressure levels in hypertensive persons |
JP2893866B2 (ja) | 1990-05-25 | 1999-05-24 | 日本油脂株式会社 | 抗不整脈薬 |
US5324323A (en) | 1992-09-09 | 1994-06-28 | Telectronics Pacing Systems, Inc. | Multiple channel cardiosynchronous myoplasty apparatus |
US5208236A (en) | 1992-09-23 | 1993-05-04 | Schering Corporation | N-(acylaminomethyl)glutaryl amino acids and use |
KR950704259A (ko) | 1992-12-11 | 1995-11-17 | 베르너 발데크 | 치환된 벤즈아제피논(Substituted Benzazepinone) |
CN1082909A (zh) * | 1993-01-03 | 1994-03-02 | 潘玉珍 | 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂 |
JPH07118229A (ja) | 1993-10-19 | 1995-05-09 | Fujisawa Pharmaceut Co Ltd | 尿素誘導体およびその製造法 |
US5760081A (en) * | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
JPH0812581A (ja) | 1994-06-30 | 1996-01-16 | Fujirebio Inc | 虚血性心疾患治療剤 |
IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
IT1277953B1 (it) | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
US6333447B1 (en) | 1996-03-29 | 2001-12-25 | The General Hospital Corporation | Transgenic model of heart failure |
US5861399A (en) | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
ATE347606T1 (de) | 1996-09-05 | 2006-12-15 | Univ California | Gentherapie für kongestives herzversagen |
US6313167B1 (en) | 1997-06-16 | 2001-11-06 | Nippon Suisan Kaisha Ltd. | Composition having capability of removing risk factor during exercise |
IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
EP1130027A1 (de) | 2000-02-29 | 2001-09-05 | Aventis Pharma Deutschland GmbH | Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben |
-
1999
- 1999-02-17 IT IT1999MI000313A patent/IT1308613B1/it active
-
2000
- 2000-02-07 EP EP20020076100 patent/EP1247523A1/de not_active Withdrawn
- 2000-02-07 PT PT00907510T patent/PT1152755E/pt unknown
- 2000-02-07 EA EA200100895A patent/EA004312B1/ru not_active IP Right Cessation
- 2000-02-07 SK SK1080-2001A patent/SK286523B6/sk not_active IP Right Cessation
- 2000-02-07 DE DE60000133.4T patent/DE60000133C5/de not_active Expired - Lifetime
- 2000-02-07 KR KR1020077019755A patent/KR20070098954A/ko not_active Application Discontinuation
- 2000-02-07 KR KR1020017010387A patent/KR100823051B1/ko active IP Right Review Request
- 2000-02-07 DK DK00907510T patent/DK1152755T3/da active
- 2000-02-07 JP JP2000599384A patent/JP5441287B2/ja not_active Expired - Lifetime
- 2000-02-07 NZ NZ513093A patent/NZ513093A/xx not_active IP Right Cessation
- 2000-02-07 CN CNB008050732A patent/CN1230159C/zh not_active Expired - Lifetime
- 2000-02-07 EP EP00907510A patent/EP1152755B1/de not_active Expired - Lifetime
- 2000-02-07 US US09/869,333 patent/US7462643B1/en not_active Expired - Fee Related
- 2000-02-07 CZ CZ20012947A patent/CZ301307B6/cs not_active IP Right Cessation
- 2000-02-07 HU HU0200111A patent/HUP0200111A3/hu unknown
- 2000-02-07 AT AT00907510T patent/ATE216230T1/de active
- 2000-02-07 PL PL350851A patent/PL209078B1/pl unknown
- 2000-02-07 WO PCT/EP2000/000957 patent/WO2000048592A1/en not_active Application Discontinuation
- 2000-02-07 AU AU29075/00A patent/AU775078B2/en not_active Expired
- 2000-02-07 IL IL14437700A patent/IL144377A0/xx active IP Right Grant
- 2000-02-07 ID IDW00200101999A patent/ID30205A/id unknown
- 2000-02-07 ES ES00907510T patent/ES2174814T3/es not_active Expired - Lifetime
- 2000-02-07 CA CA002362271A patent/CA2362271C/en not_active Expired - Lifetime
- 2000-02-07 BR BR0008153-1A patent/BR0008153A/pt not_active Application Discontinuation
-
2001
- 2001-07-17 IL IL144377A patent/IL144377A/en not_active IP Right Cessation
- 2001-07-23 ZA ZA200106029A patent/ZA200106029B/en unknown
- 2001-08-14 NO NO20013938A patent/NO328797B1/no not_active IP Right Cessation
-
2002
- 2002-08-29 HK HK02106382.1A patent/HK1044720B/zh not_active IP Right Cessation
-
2008
- 2008-08-15 US US12/192,627 patent/US20090018193A1/en not_active Abandoned
-
2010
- 2010-01-07 JP JP2010014742A patent/JP2010116414A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60000133C5 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
KR940018090A (ko) | 트리글리세라이드 | |
AU593317B2 (en) | Pharmaceutical compositions | |
EP0440341B1 (de) | Zusammensetzungen essentieller Fettsäuren und Therapie | |
DE2905979C2 (de) | Verwendung von acetylierten, destillierten Monoglyceriden zur Behandlung von Fettstoffwechselstörungen beim Menschen | |
DE60026152T2 (de) | Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs | |
KR970704433A (ko) | 의약 조성물로서의 DHA의 용도(Use of DHA as a pharmaceutical composition) | |
FR2800608B1 (fr) | Composition cosmetique contenant un ester d'acide gras hydroxyle | |
EP1135991A3 (de) | Ölzusammensetzung und ihre Verwendung | |
CN101554190A (zh) | 含两种必需脂肪酸的食用油 | |
JPS59175410A (ja) | 抗齲蝕性組成物 | |
EP2525768A1 (de) | Haftcreme für zahnprothesen | |
EP0444033A1 (de) | Topische kosmetische und pharmazeutische zubereitung | |
DE69024321T2 (de) | Oxydationsschutz eines Nahrungsmittels, eines kosmetischen Produktes oder eines pharmazeutischen Produktes | |
EP1343461A1 (de) | Verwendung von antioxidantien für mittel zur bekämpfung von mundgeruch | |
JPH11269456A (ja) | 高度不飽和脂肪酸組成物 | |
DE69711633T2 (de) | Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung | |
JPS59175422A (ja) | 抗齲蝕性組成物 | |
CN108030729A (zh) | 一种抑菌牙膏 | |
CH633769A5 (de) | Glycerintri-3,5,5-trimethylhexanoat und verwendung desselben in hautschutzmitteln. | |
DE2916573C2 (de) | Arzneimittel und Verfahren zu seiner Herstellung | |
DE300842T1 (de) | Pharmazeutische oder kosmetische zusammensetzung mit gehalt an hydrochinon und kojisaeure in liposomen. | |
DE3430166A1 (de) | Shampoo zur verhinderung von haarausfall und zur foerderung von haarwuchs | |
ES2043062T3 (es) | Procedimiento de preparacion de una composicion farmaceutica y/o dietetica. | |
DE3875637T2 (de) | Zusammensetzungen und verfahren zur behandlung von magengeschwueren. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: PHARMACIA ITALIA S.P.A., MAILAND/MILANO, IT |
|
8364 | No opposition during term of opposition | ||
8310 | Action for declaration of annulment |